HIPEC:
WHAT IT IS AND WHO NEEDS IT
CRS + HIPEC transforms peritoneal cancer from a death sentence into a potentially curable disease for selected patients β achieving 5-year survival of 50β70% in pseudomyxoma peritonei and 30β40% in colorectal peritoneal metastases.
analyticsAt a Glance
- check_circleCRS + HIPEC is standard of care for pseudomyxoma peritonei and peritoneal mesothelioma
- check_circleEligibility based on Peritoneal Cancer Index (PCI) β not just stage
- check_circle5-year OS 50β70% for PMP; 30β40% for colorectal peritoneal metastases (selected)
- check_circleHIPEC programmes available in India (Tata Memorial, Apollo) and China at significantly lower cost
What Is HIPEC and How Does It Work?
HIPEC is not a standalone procedure β it is always combined with cytoreductive surgery (CRS), which removes all visible peritoneal tumour deposits before the heated chemotherapy is delivered.
βHIPEC doesn't just treat peritoneal cancer β it targets it where it lives, delivering chemotherapy at ablative concentration directly to the peritoneal surface, bypassing the bloodβperitoneum barrier that makes systemic treatment ineffective.β
Cytoreductive Surgery (CRS)
The first phase removes all visible peritoneal tumour deposits β peritonectomy of affected surfaces, removal of involved organs (omentum, bowel segments, spleen, uterus, ovaries as required), and stripping of tumour-involved peritoneum from the abdominal wall, diaphragm, and pelvic surfaces. Completeness of Cytoreduction (CC) score CC-0 or CC-1 is required for HIPEC to be beneficial.
Hyperthermic Intraperitoneal Chemotherapy
Immediately after CRS, chemotherapy solution (mitomycin C, oxaliplatin, or cisplatin depending on tumour type) heated to 41β43Β°C is circulated through the peritoneal cavity for 30β90 minutes. Heat enhances chemotherapy penetration and cytotoxicity in residual microscopic tumour deposits β targeting cells the surgery could not visibly identify or remove.
Cancer Types Treated with CRS + HIPEC
HIPEC has different levels of evidence and survival benefit across the peritoneal malignancies it treats β eligibility and outcome vary significantly by cancer type.
| Cancer Type | Evidence Level | 5-Year OS After CRS + HIPEC | Key Eligibility Notes |
|---|---|---|---|
| Pseudomyxoma peritonei (PMP) β appendix origin | Established β international guideline standard | 50β80% (low-grade) | PCI up to 39 may be acceptable given favourable biology; early referral to specialist centre critical |
| Peritoneal mesothelioma | Established β strongest evidence for epithelioid subtype | 40β60% (epithelioid) | Sarcomatoid/biphasic subtype: poor prognosis; epithelioid with complete CRS: best outcomes |
| Colorectal peritoneal metastases | Phase III evidence (PRODIGE 7 β controversial); supported by registries | 30β45% (selected patients, CC-0) | PCI β€12β15; no systemic metastases; CC-0 or CC-1 achievable; PRODIGE 7 showed CRS alone equivalent to CRS+HIPEC in selected |
| Ovarian cancer (platinum-sensitive recurrence) | Phase III evidence (OVHIPEC-1, IIIC-IV) | 40β50% (selected) | Interval debulking surgery with HIPEC: improved OS vs surgery alone (OVHIPEC-1); needs specialist gynaecological oncology programme |
| Appendiceal cancer (mucinous) | Established β same pathway as PMP | 45β65% | Low-grade mucinous: excellent; high-grade: poorer prognosis |
| Gastric cancer peritoneal mets | Limited β retrospective and Phase II data; not standard outside Asia | 15β25% (highly selected) | PCI β€12; no distant organ mets; being evaluated in China and Korea in prospective trials |
The Peritoneal Cancer Index (PCI): The Key Eligibility Tool
The Peritoneal Cancer Index scores the extent and size of tumour deposits across 13 abdominal regions β providing a standardised measure of peritoneal disease burden that predicts completeness of cytoreduction achievability.
How PCI Is Calculated
The abdomen is divided into 13 regions (9 abdominal + 4 small bowel). Each region receives a lesion size score of 0 (no tumour), 1 (β€0.5 cm), 2 (0.5β5 cm), or 3 (>5 cm or confluent). Maximum PCI is 39. PCI is assessed at laparoscopy or laparotomy β CT/MRI underestimates PCI in 30β50% of cases.
PCI Cut-Offs for HIPEC Eligibility
Colorectal peritoneal mets: PCI β€12β15 associated with best outcomes; PCI >20 generally considered too extensive for benefit. Ovarian cancer: PCI β€20 for interval debulking + HIPEC. PMP: PCI cut-off less strict due to low-grade biology β PCI up to 39 may benefit at expert centres. CT underestimates PCI β diagnostic laparoscopy at a specialist centre provides the most accurate pre-HIPEC assessment.
Am I a HIPEC Candidate? Key Questions
HIPEC eligibility involves multiple factors beyond PCI β understanding these helps patients ask the right questions at their oncology consultation.
Favourable for HIPEC
- PCI within tumour-type thresholdPCI β€12β15 for colorectal; β€20 for ovarian; more generous for PMP/mesothelioma
- No systemic (liver, lung, bone) metastasesHIPEC addresses peritoneal disease; uncontrolled systemic disease negates the local benefit
- Good performance status (ECOG 0β1)CRS is a major 6β12 hour operation with high physiological demand β only fit patients tolerate the combined procedure safely
- Referral to specialist centre earlyPMP, appendiceal, and mesothelioma patients benefit most from early referral β before multiple prior operations scar the peritoneum and reduce CRS completeness
- Favourable tumour biology (low grade, sensitive histology)Low-grade PMP, epithelioid mesothelioma, and platinum-sensitive ovarian cancer have the best post-HIPEC outcomes
Less Likely to Benefit
- PCI above threshold with unresectable small bowel involvementExtensive small bowel involvement requiring short bowel syndrome risk or unresectable mesenteric root disease precludes complete CRS
- Active systemic metastasesLiver, lung, or bone metastases indicate systemic disease beyond peritoneal control β HIPEC will not address these sites
- High-grade aggressive histologySignet ring cell colorectal cancer, sarcomatoid mesothelioma, high-grade appendiceal cancer β poor HIPEC outcomes even with complete CRS
- Multiple prior abdominal operations with severe adhesionsPrior extensive surgery significantly increases CRS technical difficulty and time β specialist assessment required
CRS + HIPEC: Key Outcome Benchmarks
- 50β80%5-Year OS β Pseudomyxoma Peritonei (Low Grade)Best HIPEC outcomes β low-grade PMP with CC-0 CRS at specialist centres
- 30β45%5-Year OS β Colorectal Peritoneal Mets (PCI β€12, CC-0)Selected patients; vs <10% with systemic chemotherapy alone
- 3β5%30-Day Mortality at High-Volume HIPEC CentresMajor surgery β centre volume and patient selection determine safety
- 30β40%Major Complication RateBowel leak, wound infection, haematological toxicity β experienced HIPEC centres achieve lower rates
Related Surgical Oncology Resources
Further reading on advanced cancer surgery and peritoneal disease management.
Frequently Asked Questions
HIPEC: Eligibility and What to Expect
How long does the CRS + HIPEC operation take and what is recovery like?
CRS + HIPEC is a major 6β12 hour operation, depending on the extent of peritoneal disease and organs requiring resection. Hospital stay is typically 10β14 days, with 2β3 days in ICU immediately post-operatively. Full recovery takes 6β8 weeks. Major complications (bowel leak, wound infection, haematological toxicity) occur in 30β40% of patients β managed with experienced multidisciplinary post-operative support. Patients return to adjuvant systemic therapy 6β8 weeks after surgery when recovered. CRS + HIPEC at high-volume specialist centres has 30-day mortality of 3β5%.
My oncologist has not mentioned HIPEC β should I ask about it?
Yes β particularly if you have pseudomyxoma peritonei, peritoneal mesothelioma, appendiceal cancer, or limited colorectal peritoneal metastases with no systemic disease. HIPEC is a subspecialty procedure that most general oncologists do not manage β it requires referral to a dedicated CRS + HIPEC programme. Studies show significant rates of under-referral for HIPEC-eligible patients. CancerFax can arrange a specialist assessment of your imaging and records by an experienced peritoneal oncology team to determine whether CRS + HIPEC applies to your case.
Is HIPEC available in India and China?
Yes. Tata Memorial Hospital in Mumbai has the most established HIPEC programme in India β with dedicated peritoneal oncology surgeons, operating theatre infrastructure, and active outcomes data. Apollo Hospitals also offers HIPEC. In China, multiple academic centres perform CRS + HIPEC, particularly for colorectal and gastric peritoneal metastases. Costs in India and China are 60β75% lower than in Western Europe or the USA. CancerFax can identify the most appropriate HIPEC programme based on your specific cancer type, PCI estimate, and overall health status, and coordinate a pre-procedure assessment.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is CRS + HIPEC an Option for Your Peritoneal Cancer?
Upload your CT/MRI imaging and oncology records. CancerFax will assess your PCI, review HIPEC eligibility, and connect you with specialist peritoneal oncology programmes in India or China.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.